Sp7/Osterix Antibody [J12J9]

Catalog No.: F1545

Application: Reactivity: Mouse, Rat, Human

Lane 1: Saos-2

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:30 IHC1:1000

Application
WB, IP, IHC

Source
Rabbit Monoclonal Antibody

Reactivity
Mouse, Rat, Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
45 kDa 45 kDa, 47 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
Sp7/Osterix Antibody [J12J9] detects endogenous levels of total Sp7/Osterix protein.

Clone
J12J9

Synonym(s)
OSX; SP7; Transcription factor Sp7; Zinc finger protein osterix

Background
Sp7, also known as Osterix (Osx), is a zinc-finger transcription factor of the Sp/KLF family that functions as a master regulator of osteoblast differentiation downstream of Runx2, essential for bone formation in vertebrates and primarily expressed in osteoblasts, osteocytes, and chondrocytes. Sp7 contains a proline-rich N-terminal transactivation domain and a C-terminal DNA-binding domain with three C2H2-type zinc finger motifs highly homologous to Sp1/Sp3/Sp4, though amino acid variations in the zinc finger reduce affinity for canonical GC-boxes and enable interaction with AT-rich motifs via protein-protein contacts. Sp7 promotes mesenchymal progenitor commitment to mature osteoblasts by inducing genes like Col1a1, Bglap (osteocalcin), Ibsp (bone sialoprotein), Sparc (osteonectin), and Alp while suppressing chondrogenesis; it acts primarily as a co-activator in complexes with Dlx family homeodomain factors (e.g., Dlx5) that bind AT-rich homeodomain-response elements in osteoblast enhancers, driving synergistic transcriptional activation via the Sp7 N-terminus. This non-canonical mechanism supports osteocyte maturation, lacuno-canalicular network formation, bone matrix mineralization, and adult bone homeostasis through pathways like BMP, Wnt/β-catenin, and MAPK signaling. Mutations in SP7 cause osteogenesis imperfecta and osteoporosis by disrupting osteoblast differentiation and bone mass maintenance.

Background

Sp7, also known as Osterix (Osx), is a zinc-finger transcription factor of the Sp/KLF family that functions as a master regulator of osteoblast differentiation downstream of Runx2, essential for bone formation in vertebrates and primarily expressed in osteoblasts, osteocytes, and chondrocytes. Sp7 contains a proline-rich N-terminal transactivation domain and a C-terminal DNA-binding domain with three C2H2-type zinc finger motifs highly homologous to Sp1/Sp3/Sp4, though amino acid variations in the zinc finger reduce affinity for canonical GC-boxes and enable interaction with AT-rich motifs via protein-protein contacts. Sp7 promotes mesenchymal progenitor commitment to mature osteoblasts by inducing genes like Col1a1, Bglap (osteocalcin), Ibsp (bone sialoprotein), Sparc (osteonectin), and Alp while suppressing chondrogenesis; it acts primarily as a co-activator in complexes with Dlx family homeodomain factors (e.g., Dlx5) that bind AT-rich homeodomain-response elements in osteoblast enhancers, driving synergistic transcriptional activation via the Sp7 N-terminus. This non-canonical mechanism supports osteocyte maturation, lacuno-canalicular network formation, bone matrix mineralization, and adult bone homeostasis through pathways like BMP, Wnt/β-catenin, and MAPK signaling. Mutations in SP7 cause osteogenesis imperfecta and osteoporosis by disrupting osteoblast differentiation and bone mass maintenance.

References
[1] Hojo H, et al. Int J Mol Sci. 2022 May 18;23(10):5647. [2] Hojo H, et al. Dev Cell. 2016 May 9;37(3):238-53.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%